TrialSignal
Clinical trial intelligence report
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04658914
Status
COMPLETED
Phase
Phase 2
Sponsor
Centre for Infectious Disease Research in Zambia
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates a novel trivalent VP8 subunit rotavirus vaccine in combination with the existing Rotarix vaccine to enhance immune response in infants in Zambia. The study aims to address the ongoing morbidity and mortality associated with rotavirus infections despite existing vaccination efforts.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04658914
Indication
Diarrhea
Modality
cell therapy
Target
Rotavirus
Intervention
Rotarix, Trivalent P2-VP8
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.